// App-Quantinova.ai

2566 : Phase I study of the PI3K/mTOR inhibitor gedatolisib (PF-05212384) in combination with docetaxel, cisplatin, and dacomitinib.

Researchers

Presenter

  • Zev A. Wainberg

Principal Investigators

  • Geoffrey Shapiro

  • Giuseppe Curigliano

  • Rebecca Sophie Kristeleit

  • Stephen Leong

  • Maria Alsina

  • Michele Milella

  • Carolyn D. Britten

  • Karen A. Gelmon

  • Anthony J. Olszanski

  • Ulka N. Vaishampayan

  • Jose A. Lopez-Martin

  • Kenneth Alan Kern

  • Kristen J. Pierce

  • Rachelle Perea

  • Brett Houk

  • Nuzhat Pathan

  • Albiruni R. Razak

Medical Centers

  • David Geffen School of Medicine, University of California Los Angeles, Los Angeles, CA

  • Dana-Farber Cancer Institute, Boston, MA

  • Istituto Europeo di Oncologia, Milano, Italy

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • University of Colorado Cancer Center, Aurora, CO

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Regina Elena National Cancer Institute, Rome, Italy

  • Department of Medicine, Hollings Cancer Center, Medical University of South Carolina, Charleston, SC

  • British Columbia Cancer Agency, Vancouver, BC, Canada

  • Fox Chase Cancer Center, Temple Health, Philadelphia, PA

  • Karmanos Cancer Institute, Detroit, MI

  • '12 de Octubre' University Hospital & Research Institute, Madrid, Spain

  • Pfizer Inc, San Diego, CA

  • Pfizer Oncology, Groton, CT

  • Pfizer Worldwide Research and Development, San Diego, CA

  • Pfizer Oncology, La Jolla, CA

  • Pfizer Inc, San Diego, CA

  • Drug Development Program, Princess Margaret Cancer Centre, Toronto, ON, Canada

Locations

  • Canada

  • Italy

  • Spain

  • United Kingdom

  • United States

Companies

  • PharmAbcine Inc.

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Non Small Cell Lung cancer

  • Squamous cell carcinoma of the head and neck

  • Prostate cancer

  • Gynaecological cancer

  • Breast cancer

  • Lung Cancer

  • Triple-negative breast cancer

Biomarkers

  • Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit alpha isoform

  • erb-b2 receptor tyrosine kinase 2

  • Serine/threonine-protein kinase mTOR

Drug/Treatment

  • dacomitinib

  • Gedatolisib

  • Docetaxel

  • Cisplatin

Outcome

  • Unknown

Study Design

  • Pharmacokinetics

Phase

  • I

Study Id's

  • NCT01920061

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved